Re: Gilead's GS-5829 flops in mCRPC

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

fouremm

Rank: President [?]

Points: 3330 [?]

Votes: 34 Score: 3.8 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Gilead's GS-5829 flops in mCRPC

in response to

Re: Gilead's GS-5829 flops in mCRPC

tada

posted on Jul 19, 2022 11:47PM

Tada, I believe GS-5829 (Alobresib) was developed in house by Gilead. I think you are are confusing this with Gilead's $21B purchase of Trodelvy, a breast cancer drug that Don was babbling on about a few presentations ago.

4 Recommendations

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Please to post a reply